Influenza A viruses (IAV) are a significant public health challenge that result in the emergence of antigenically shifted or highly virulent strains.Antiviral resistance to currently available drugs such as adamantanes or neuraminidase inhibitors has appeared rapidly,therefore,it is imperative to develop potent anti-IAV agents with different mode of action.